News
Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...
Andrew Frank and Katherine C. Pearson, QUOI MediaAlzheimer’s disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...
The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...
Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...
HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...
What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...
With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...
The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by ...
Almost a million people in the UK are living with dementia, but about a third of them do not have a diagnosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results